Current status of biosimilars in the treatment of inflammatory bowel diseases [PDF]
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very
Dong Il Park
doaj +1 more source
Letter: treatment with subcutaneous CT‐P13 in Crohn’s disease patients with intravenous infliximab failure [PDF]
LINKED CONTENTThis article is linked to Hanzel et al papers.
Caron, Bénédicte +3 more
openaire +3 more sources
Kontrollierte Einführung des Infliximab-Biosimilars CT-P13 bei Patienten mit Morbus Crohn und Colitis ulcerosa in einer großen deutschen Zentrumskohorte [PDF]
Einleitung: Das Infliximab Biosimilar CT-P13 wurde 2013 von der EMA im Rahmen eines Extrapolationsprozesses für die Behandlung von chronisch entzündlichen Darmerkrankungen (CED) ohne Zulassungsstudien genehmigt.
Röder, Helene
core +1 more source
Background: Crohn disease (CD) is a chronic inflammatory disease that affects quality of life. There are several drugs available for the treatment of CD, but their relative efficacy is unknown due to a lack of high-quality head-to-head randomized ...
Guozhi Wu +11 more
doaj +1 more source
Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective [PDF]
Nimer S. Alkhatib +12 more
doaj +2 more sources
Background: CT-P13 is a biosimilar of Remicade©, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD.
Guerra Veloz, María Fernanda +8 more
core +2 more sources
Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up [PDF]
Patricia Shu Kurizky +2 more
doaj +2 more sources
The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease [PDF]
The advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost ...
Devika Kapuria, Rajiv Chhabra
openaire +1 more source
Beyond Radical Emitters: Hot‐Exciton Electroluminescence From Singlet Diradicaloids
The first hot‐exciton mechanism in a singlet diradicaloid is demonstrated in a polychlorinated Thiele hydrocarbon‐based organic light‐emitting transistor. Reverse intersystem crossing involving the T2 and bright singly excited states enables electroluminescence beyond the 25% spin‐statistical limit, leading to remarkable external quantum efficiency ...
Mario Prosa +12 more
wiley +2 more sources
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. [PDF]
Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn's disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there are insufficient data from well-controlled trials to support non-medical ...
Bernard EJ, Fedorak RN, Jairath V.
europepmc +4 more sources

